[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"type-ii-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:type-ii-diabetes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,63,91,123,148],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100605783","the-groceries-aimed-at-increasing-nutrition-study-100605783",false,"NCT07167004","The GRoceries Aimed at Increasing Nutrition Study","Prompting a Switch From Refined Grains to Whole Grains in an Online Grocery Store Using Marketing Nudges and Financial Incentives","GRAINS","Inclusion Criteria:\n\n* Age 45 - 70 years.\n* Able to provide consent.\n* Resident of Philadelphia, Bucks, Delaware, Chester, or Montgomery Counties in Pennsylvania.\n* Consume \\\u003C5 servings of whole grains per week.\n* Use online grocery shopping at least once per month.\n* Have access to a credit or debit card to pay for groceries purchased.\n* Have reliable internet access.\n* Speak English.\n* Penn Medicine patient diagnosed with prediabetes or diabetes (identified using ICD-10 codes R73.03, E11).\n\nExclusion Criteria:\n\n* Does not meet all the inclusion criteria.\n* Not able to speak English.\n* Not able to provide consent.","ALL","45 Years","70 Years",{"count":21,"type":22},216,"ESTIMATED","INTERVENTIONAL",[25],"NA","Only 2% of Americans meet the recommended levels of whole grain consumption, despite its association with reduced risk of type 2 diabetes. This study aims to assess if consumers with prediabetes or type 2 diabetes can be encouraged to switch from buying refined grain products to whole grain products when shopping for groceries online. The study will use personalized marketing strategies, with or without discounts which adjust based on purchasing behavior, to promote whole grain consumption.",[28,29,30,31,32,33,34,35,36],"Type 2 Diabetes","Type II Diabetes Mellitus","Type II Diabetes","Pre-diabetes","Pre-diabetic","Pre-diabetic State","Type 2 Diabetes Mellitus (T2DM)","Type 2 Diabetes Mellitus","Type 2 Diabetes (T2DM)",[38,39,40,41,42,43,44,45,46,47,48,49],"chronic disease","diabetes","diabetes mellitus","type II diabetes","type 2 diabetes","pre-diabetes","prediabetes","whole grains","behavioral economics","marketing nudges","financial incentives","food is medicine","RECRUITING","2026-05-15",{"date":53,"type":54},"2026-05-19","ACTUAL",{"date":56,"type":54},"2025-10-14",{"date":58,"type":22},"2027-02-16",{"name":60,"class":61},"University of Pennsylvania","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":75,"briefSummary":77,"conditions":78,"keywords":79,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":62},"100441421","phase-3-efficacy-and-safety-of-piemonte-association-in-the-treatment-of-type-ii-diabetes-mellitus-100441421","NCT05028140","Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus","National, Multicenter, Randomized, Double-blind, Triple-dummy, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus","PIEMONTE","Inclusion Criteria:\n\n* Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the consent form;\n* Diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goal of HbA1c with previous dietary, physical exercise, and previous therapies at stable doses within 3 months.\n\nExclusion Criteria:\n\n* Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of participants;\n* History of alcohol abuse or illicit drug use;\n* Participation in a clinical trial in the year prior to this study;\n* Pregnancy or risk of pregnacy and lactating participants;\n* Known hypersensitivity to any of the formula compounds;\n* Type 1 diabetes.","18 Years","85 Years",{"count":74,"type":22},480,[76],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus",[30],[80],"Type II diabetes mellitus","2025-12-01",{"date":83,"type":54},"2025-12-08",{"date":85,"type":54},"2024-10-08",{"date":87,"type":22},"2027-09",{"name":89,"class":90},"EMS","INDUSTRY",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":101,"conditions":102,"keywords":111,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":62},"100519889","lifestyle-medicine-establishing-clinical-approaches-to-chronic-disease-for-rural-patients-100519889","NCT06049420","Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients","Inclusion Criteria:\n\n* Program admittance will be restricted to patients with 2+ diagnosed diseases that have sufficient evidence for the efficacy of exercise therapy (obesity, hyperlipidemia, metabolic syndrome, polycystic ovarian syndrome, type II diabetes, hypertension, coronary heart disease, heart failure, depression, anxiety)\n* physician referral required\n\nExclusion Criteria:\n\n* no chronic disease diagnosis, lack of physician referral, unwillingness to participate.","64 Years",{"count":99,"type":22},95,[25],"Developed nations worldwide are currently enduring a health crisis, as chronic diseases continue to decrease quality of life and promote additional disease states or even death for much of the population. Rural populations are at a particular disadvantage, as they lack access to health clubs, wellness programs and similar resources that are more available in urban areas. Although pharmaceutical therapies have continued to show therapeutic advancements, the rates of disease onset and death from chronic disease has not seen similar improvements, and in fact continue to worsen. Excitingly, significant evidence has been published demonstrating an affordable, effective treatment to directly treat and prevent these chronic diseases, but few have demonstrated successful implementation of this therapy, which is improved lifestyle. Specifically, physical activity and healthy body composition are powerful therapeutics that have been demonstrated to effectively combat and prevent chronic diseases. Additionally, improving these lifestyle factors are often more effective than pharmaceutical interventions without the wide range of side effects. Unfortunately, barriers exist on multiple tiers in the practice of family medicine that demote the implementation of lifestyle medicine. To better serve patients at risk of, or suffering from chronic disease, the investigators are seeking to establish a lifestyle medicine prescription program for rural West Virginia. This program will provide patient education on the benefits of physical activity, body composition, and help patients identify strategies to implement healthy lifestyle choices that can be sustainable for the long-term. Patients will be advised on local opportunities to increase physical activity (yoga studio, martial arts, fitness facilities, aquatic center, etc.) and provided access to the facilities they are most likely to adhere to regularly. They will also be provided training on exercise techniques, equipment, and facilities to increase familiarity and comfort in these settings.",[103,104,105,106,107,108,109,30,110],"Obesity","Hyperlipidemias","Polycystic Ovary Syndrome","Hypertension","Coronary Heart Disease","Heart Failure","Depression, Anxiety","Metabolic Syndrome",[112,38,113],"lifestyle","physical activity","2025-07-21",{"date":116,"type":54},"2025-07-25",{"date":118,"type":54},"2025-02-01",{"date":120,"type":22},"2027-09-01",{"name":122,"class":61},"West Virginia School of Osteopathic Medicine",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":127,"acronym":128,"eligibilityCriteria":129,"healthyVolunteers":11,"sex":17,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":23,"phases":134,"briefSummary":136,"conditions":137,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":142,"completionDateStruct":144,"leadSponsor":146,"locationsCount":62},"100493723","phase-4-effect-of-tirzepatide-on-progression-of-coronary-atherosclerosis-using-mdct-100493723","NCT05708859","Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT","T-PLAQUE","Inclusion Criteria:\n\n1. Male or female 40 years to 80 years of age at signing of informed consent\n2. Type 2 DM of minimum 5 years duration with HbA1c ≥7.0% to ≤10.5%\n3. Body mass index (BMI) ≥25 kilograms per meter squared (kg\u002Fm²)\n4. Presence of two discrete coronary artery plaques with visual diameter stenosis \\>20% on CCTA\n5. At the baseline visit, participants must be on a stable (\\>4 weeks) regiment of diabetes medications.\n6. Patients using oral hormonal contraceptives must switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation\n\nExclusion Criteria:\n\n1. Have had a major cardiovascular event within the last 60 days\n2. Have type 1 diabetes mellitus\n3. Current use of GLP1-RA\n4. Have a history of severe hypoglycemia and\u002For hypoglycemia unawareness within the last 6 months\n5. Are currently planning treatment for diabetic retinopathy and\u002For macular edema\n6. Have history of, or currently planning a coronary, carotid, or peripheral artery revascularization (ie - stent, bypass)\n7. Have a history of pancreatitis\n8. Have a history of ketoacidosis or hyperosmolar state\u002Fcoma\n9. Have a known clinically significant gastric emptying abnormality, have undergone or currently planning any gastric outlet obstruction, or have undergone or currently planning any gastric bypass (bariatric) surgery or restrictive bariatric surgery\n10. Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years\n11. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)\n12. Have had a blood transfusion or severe blood loss within 90 days prior to screening or have known hematological conditions that may interfere with HbA1c measurement\n13. Planned or Prior Bypass surgery\n14. Contradiction for CCTA (e.g. serious allergic reaction to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA visit as assessed by the imaging core lab.\n15. Uncontrolled severe hypertension: systolic blood pressure \\> 180 mmHg or diastolic BP \\> 100 mm Hg prior to randomization (assessed at the screening visit) despite antihypertensive therapy\n16. Heart Failure NYHA Class III or IV at the screening visit\n17. Renal insufficiency (eGFR \\\u003C40 ml\u002Fmin\u002F1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the screening visit.\n18. Hospitalization for major cardiovascular event including heart failure in the past 2 months","40 Years","80 Years",{"count":133,"type":22},120,[135],"PHASE4","A multi-center, randomized, double-blind, placebo-controlled, parallel-group phase IV Study evaluating the effects of tirzepatide on atherosclerotic plaque progression assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of type II Diabetes (T2DM) and atherosclerosis.",[30,138],"Atherosclerosis","2024-10-10",{"date":141,"type":54},"2024-10-15",{"date":143,"type":54},"2024-01-02",{"date":145,"type":22},"2026-05",{"name":147,"class":61},"Matthew J. Budoff",{"id":149,"slug":150,"hasResults":11,"nctId":151,"briefTitle":152,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":17,"minAge":71,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":62},"100444999","dundrum-forensic-redevelopment-evaluation-study-d-forest-study-100444999","NCT05074732","Dundrum Forensic Redevelopment Evaluation Study: D-FOREST Study.","D-FOREST","Inclusion Criteria:\n\n* Admitted to the National Forensic Mental Health Service (NFMHS) Ireland after 1st December 2019 until 7 years after the transfer of the National Service to the newly developed complete National Forensic Service at Portrane, North Dublin, Ireland.\n\nExclusion Criteria:\n\n* This study comprises a complete cohort of admissions to the NFMHS. All adult patients admitted during the time period will be included in the study, regardless of their length of stay.",{"count":156,"type":22},350,"OBSERVATIONAL","The DUNDRUM Forensic Redevelopment Evaluation study (D-FOREST study) is a multi-site comprehensive evaluation of a complete National Forensic Mental Health Service. The study will have a prospective, observational, longitudinal design which will permit the evaluation of benefit over time for individual patients, groups of patients and the evaluation of the benefit in terms of service based outcomes of the redevelopment of a complete National Forensic Mental Health Service e.g. effects on waiting list times, length of stay. The study will systematically evaluate multiple domains of recovery in a complete National Forensic Service, including patients' physical health, mental health, offending behaviours and social and occupational functioning.",[160,161,162,163,164,165,103,30,166,167,168,169],"Schizophrenia","Forensic Psychiatry","Outcome Measure","Violence","Personality Disorders","Recovery","Cardiovascular Diseases","Frailty","Psychosis","Treatment-resistant Schizophrenia","2021-10-02",{"date":172,"type":54},"2021-10-12",{"date":174,"type":54},"2019-12-01",{"date":176,"type":22},"2027-12-31",{"name":178,"class":61},"Health Service Executive, Ireland"]